{"id":"cetrotide-injectable-product","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By antagonizing GnRH receptors in the pituitary gland, Cetrotide rapidly suppresses gonadotropin release without the initial flare effect seen with GnRH agonists. This leads to controlled suppression of ovarian steroid production, making it useful for controlled ovarian hyperstimulation in assisted reproductive technology cycles.","oneSentence":"Cetrotide is a gonadotropin-releasing hormone (GnRH) antagonist that blocks GnRH receptors to suppress luteinizing hormone and follicle-stimulating hormone secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:24.079Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Controlled ovarian hyperstimulation in assisted reproductive technology (ART) and in vitro fertilization (IVF) cycles"}]},"trialDetails":[{"nctId":"NCT07340827","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)","status":"RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2026-02-05","conditions":"Infertility","enrollment":333},{"nctId":"NCT06608186","phase":"PHASE1, PHASE2","title":"Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!","status":"COMPLETED","sponsor":"Ahmed Saad","startDate":"2024-10-01","conditions":"PCOS (Polycystic Ovary Syndrome)","enrollment":50},{"nctId":"NCT06571214","phase":"PHASE4","title":"Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment","status":"NOT_YET_RECRUITING","sponsor":"Nanjing University","startDate":"2024-09-01","conditions":"Infertility","enrollment":300},{"nctId":"NCT04447872","phase":"NA","title":"The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol","status":"UNKNOWN","sponsor":"Northwell Health","startDate":"2020-09-15","conditions":"Infertility, Diminished Ovarian Reserve, IVF","enrollment":142},{"nctId":"NCT04931355","phase":"NA","title":"Acupuncture in the Freeze-all IVF Cycle","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-06-01","conditions":"Acupuncture, Female Infertility","enrollment":90},{"nctId":"NCT04616729","phase":"PHASE1, PHASE2","title":"DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2022-11-01","conditions":"Breast Cancer Female","enrollment":30},{"nctId":"NCT04537078","phase":"PHASE3","title":"Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders","status":"COMPLETED","sponsor":"El Shatby University Hospital for Obstetrics and Gynecology","startDate":"2020-09-01","conditions":"Infertility, Female","enrollment":90},{"nctId":"NCT04854707","phase":"","title":"An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data","status":"COMPLETED","sponsor":"IVFarma LLC","startDate":"2020-01-12","conditions":"Reproductive Issues, Reproductive Disorder, Fertility Disorders","enrollment":5484},{"nctId":"NCT04935073","phase":"PHASE3","title":"Traditional Chinese Medicine Herbs in the Freeze-all IVF Cycle","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2021-06-15","conditions":"Infertility, Female","enrollment":90},{"nctId":"NCT04842825","phase":"PHASE3","title":"Sequential Therapy of TCM Herbs to Improve the Success Rate of IVF-ET in Diminished Ovarian Reserve Patients","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2021-04-15","conditions":"Infertility, Female","enrollment":200},{"nctId":"NCT03181685","phase":"PHASE4","title":"Patients' Preference for Subcutaneous or Vaginal Progesterone as Luteal Support in IVF/ICSI Cycles","status":"TERMINATED","sponsor":"Andros Day Surgery Clinic","startDate":"2016-12-20","conditions":"Infertility, In Vitro Fertilization","enrollment":60},{"nctId":"NCT01590173","phase":"PHASE2, PHASE3","title":"Addition of Prednisolone and Heparin in Patients Undergoing IVF With Failed IVF Cycles","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2012-01","conditions":"Infertility","enrollment":86}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cetrotide Injectable Product","genericName":"Cetrotide Injectable Product","companyName":"El Shatby University Hospital for Obstetrics and Gynecology","companyId":"el-shatby-university-hospital-for-obstetrics-and-gynecology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cetrotide is a gonadotropin-releasing hormone (GnRH) antagonist that blocks GnRH receptors to suppress luteinizing hormone and follicle-stimulating hormone secretion. Used for Controlled ovarian hyperstimulation in assisted reproductive technology (ART) and in vitro fertilization (IVF) cycles.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}